Mereo BioPharma Group plc
MREONasdaqCIK 1719714HealthcareFiscal year ends Dec 31
Reports and events: 186 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-1907:52 ET | 8-K | 3.01 Delisting notice | 0001193125-26-356168 |
| 2026-08-1108:37 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-343533 |
| 2026-08-1108:26 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-343519 |
| 2026-08-1108:07 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-343482 |
| 2026-05-1410:22 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-223071 |
| 2026-05-1208:56 ET | 8-K/A | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-218290 |
| 2026-05-1208:03 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-218232 |
| 2026-05-1207:33 ET | 8-K | 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001193125-26-218192 |
| 2026-04-0906:51 ET | DEF 14A | Proxy statementPeriod 2026-04-08 | 0001193125-26-148832 |
| 2026-03-2706:10 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-127253 |
| 2026-03-1908:52 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-115226 |
| 2026-03-1908:41 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-115211 |
| 2026-02-1716:30 ET | 8-K | 3.01 Delisting notice | 0001193125-26-054787 |
| 2026-01-1208:09 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-009829 |
| 2025-12-2908:54 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-332520 |
| 2025-11-1016:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-274319 |
| 2025-11-1016:15 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-274272 |
| 2025-08-1207:55 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001193125-25-178489 |
| 2025-08-1207:40 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-106924 |
| 2025-07-1006:49 ET | 8-K | 8.01 Other events | 0000950170-25-094921 |
| 2025-05-1416:30 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-071485 |
| 2025-05-1307:57 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-069816 |
| 2025-05-1307:48 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-069811 |
| 2025-04-0806:41 ET | DEF 14A | Proxy statementPeriod 2025-05-13 | 0000950170-25-051800 |
| 2025-03-2607:44 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-044787 |
| 2025-03-2607:38 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-044783 |
| 2025-01-1306:32 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-004523 |
| 2024-11-1208:13 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-124637 |
| 2024-11-1207:40 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-124598 |
| 2024-08-1308:19 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-095777 |
| 2024-08-1308:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-199430 |
| 2024-06-1716:32 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-072315 |
| 2024-06-1416:30 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-161662 |
| 2024-06-1221:15 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-159393 |
| 2024-05-2316:16 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-24-145983 |
| 2024-05-1516:19 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-060497 |
| 2024-05-1516:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-139366 |
| 2024-04-2407:30 ET | DEF 14A | Proxy statementPeriod 2024-05-23 | 0001193125-24-108454 |
| 2024-04-1614:58 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-047715 |
| 2024-04-1507:30 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-24-095508 |
| 2024-03-2717:20 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-037348 |
| 2024-03-2716:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-078800 |
| 2024-01-0807:08 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-003868 |
| 2023-12-1816:10 ET | 6-K | Report of a foreign private issuerPeriod 2023-12-18 | 0001193125-23-297624 |
| 2023-11-2916:15 ET | 6-K | Report of a foreign private issuerPeriod 2023-11-29 | 0001193125-23-285182 |
| 2023-11-2008:45 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-23-119750 |
| 2023-11-1607:01 ET | 6-K | Report of a foreign private issuerPeriod 2023-11-16 | 0001193125-23-278320 |
| 2023-11-1507:56 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-23-118442 |
| 2023-11-1307:31 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-23-116684 |
| 2023-11-0807:06 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-23-115492 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.